VANCOUVER, June 8 /PRNewswire-FirstCall/ -- Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF), today issued its 12th CEO Message from Jim DeMesa, MD, President & CEO.
To obtain a copy of the CEO Message please visit the Micrologix web site at http://www.mbiotech.com/ or contact Investor Relations at 1-800-665-1968, Extension 241.
Micrologix Biotech Inc. is engaged in the research, development, and commercialization of drugs that advance therapy, improve health, and enrich lives. The Company has four product candidates in human clinical development, multiple product opportunities in preclinical development, and several early- stage technologies in various stages of research and evaluation. On April 15, 2004, Micrologix announced an agreement to acquire San Diego-based MitoKor, Inc., a biotechnology company focused on the research and development of products for degenerative diseases such as Alzheimer's disease, arthritis, and glaucoma.
Jonathan Burke Gino de Jesus/ Dian Griesel, Ph.D
Investor & Media Relations The Investor Relations Group
Micrologix Biotech Inc. Telephone: 212-825-3210
Telephone: 604-221-9666 Ext 241 Email: firstname.lastname@example.org
Toll Free: 1-800-665-1968
Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in the Company's Annual Information Form and Annual Report on Form 20-F, forthcoming news releases and other filings with the Canadian securities regulatory authorities and the U.S. Securities & Exchange Commission. Forward-looking statements are based on our current expectations and Micrologix is not obligated to update such information to reflect later events or developments.
The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
Micrologix Biotech Inc.
CONTACT: Jonathan Burke, Investor & Media Relations, Micrologix BiotechInc., Telephone: (604) 221-9666 Ext 241, Toll Free: 1-800-665-1968, Email:email@example.com; Gino de Jesus/Dian Griesel, Ph.D, The InvestorRelations Group, Telephone: (212) 825-3210, Email: firstname.lastname@example.org;To request a free copy of this organization's annual report, please go tohttp://www.newswire.ca/ and click on reports@cnw.